ERP123730 PRJEB40126 ena-STUDY-Centre de Recherche Saint Antoine-01-09-2020-12:54:19:991-691 Glycans as immune-checkpoints in cancer: removal of branched N-glycans prevents colorectal cancer progression through increasing immune recognition and anti-tumor immune response Tumor growth is accompanied with dramatic changes in the cellular glycome, such as the aberrant expression of complex branched N-glycans. However, it remains elusive the role of this pro-tumoral N-glycan in immune evasion and whether its removal contributes to enhancement of immune recognition and to unleash an antitumor immune response. We demonstrated that branched N-glycans are used by colorectal cancer (CRC) cells to escape immune recognition, instructing the creation of immunosuppressive networks through inhibition of IFN?. The removal of this “glycan-mask” exposed immunogenic mannose glycans that potentiated immune recognition by DC-SIGN-expressing immune cells, resulting in an effective antitumor immune response. We revealed a glycoimmune checkpoint in CRC, highlighting the therapeutic efficacy of its deglycosylation to potentiate immune recognition and, thus, improving cancer immunotherapy. GlycanCRC Tumor growth is accompanied with dramatic changes in the cellular glycome, such as the aberrant expression of complex branched N-glycans. However, it remains elusive the role of this pro-tumoral N-glycan in immune evasion and whether its removal contributes to enhancement of immune recognition and to unleash an antitumor immune response. We demonstrated that branched N-glycans are used by colorectal cancer (CRC) cells to escape immune recognition, instructing the creation of immunosuppressive networks through inhibition of IFN?. The removal of this “glycan-mask” exposed immunogenic mannose glycans that potentiated immune recognition by DC-SIGN-expressing immune cells, resulting in an effective antitumor immune response. We revealed a glycoimmune checkpoint in CRC, highlighting the therapeutic efficacy of its deglycosylation to potentiate immune recognition and, thus, improving cancer immunotherapy. ENA-FIRST-PUBLIC 2020-10-01 ENA-LAST-UPDATE 2020-09-01